DE69838099D1 - Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen - Google Patents

Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen

Info

Publication number
DE69838099D1
DE69838099D1 DE69838099T DE69838099T DE69838099D1 DE 69838099 D1 DE69838099 D1 DE 69838099D1 DE 69838099 T DE69838099 T DE 69838099T DE 69838099 T DE69838099 T DE 69838099T DE 69838099 D1 DE69838099 D1 DE 69838099D1
Authority
DE
Germany
Prior art keywords
quinazolinenone
reproductions
pharmaceutical compositions
containing pharmaceutical
preventing vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69838099T
Other languages
English (en)
Other versions
DE69838099T2 (de
Inventor
Mark Pines
Arnon Nagler
Israel Vlodavsky
Hua-Quan Miao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Agricultural Research Organization of Israel Ministry of Agriculture filed Critical Hadasit Medical Research Services and Development Co
Publication of DE69838099D1 publication Critical patent/DE69838099D1/de
Application granted granted Critical
Publication of DE69838099T2 publication Critical patent/DE69838099T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69838099T 1997-02-11 1998-02-11 Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen Expired - Fee Related DE69838099T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US797703 1997-02-11
US08/797,703 US6028075A (en) 1997-02-11 1997-02-11 Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
PCT/IL1998/000070 WO1998034613A1 (en) 1997-02-11 1998-02-11 Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Publications (2)

Publication Number Publication Date
DE69838099D1 true DE69838099D1 (de) 2007-08-30
DE69838099T2 DE69838099T2 (de) 2008-04-30

Family

ID=25171574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838099T Expired - Fee Related DE69838099T2 (de) 1997-02-11 1998-02-11 Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen

Country Status (11)

Country Link
US (3) US6028075A (de)
EP (1) EP1007044B1 (de)
JP (1) JP2001518075A (de)
KR (1) KR100518106B1 (de)
AT (1) ATE367158T1 (de)
AU (1) AU738516B2 (de)
CA (1) CA2280850C (de)
DE (1) DE69838099T2 (de)
ES (1) ES2290983T3 (de)
IL (1) IL131349A (de)
WO (1) WO1998034613A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
EP0991411A4 (de) * 1997-03-31 2000-05-31 Agricultural Res Org Behandlung von lungenfibrose
AU756437B2 (en) * 1998-08-13 2003-01-16 Agricultural Research Organization, Ministry Of Agricultural, State Of Israel Inhibition of pathogenic processes related to tissue trauma
HUP0300845A2 (hu) * 1999-09-09 2003-07-28 Hadasit Medical Research Services And Development Company Ltd. Sebgyógyulást elősegítő készítmény, eljárás az előállítására és alkalmazása
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CA2444704C (en) * 2001-04-23 2012-07-10 University Of Virginia Patent Foundation Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
US20030119834A1 (en) * 2001-09-05 2003-06-26 Bamdad Cynthia C. Compositions and methods of treatment of cancer
EP2116248A1 (de) * 2001-09-05 2009-11-11 Minerva Biotechnologies Corporation Zusammensetzungen und Verfahren zur Behandlung von Krebs
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
WO2004039308A2 (en) * 2002-10-31 2004-05-13 State Of Israel, Ministry Of Agriculture Quinazolinone compositions for regulation of gene expression related to pathological processes
JP2008524159A (ja) * 2004-12-15 2008-07-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ＮＥＰ阻害剤、内因性エンドセリン産生系の阻害剤およびＨＭＧＣｏＡレダクターゼ阻害剤を含有する医薬組成物
CA2600046A1 (en) * 2005-02-23 2006-08-31 Collgard Biopharmaceuticals Ltd. Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
US20070160640A1 (en) * 2006-01-12 2007-07-12 Eun-Hyun Jang Halofuginone delivering vascular medical devices
AU2007238816B2 (en) * 2006-04-10 2012-12-06 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
US8883190B2 (en) * 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
EP2111450A2 (de) 2007-01-16 2009-10-28 Yissum Research Development Company of the Hebrew University of Jerusalem Nukleinsäurekonstrukte und verfahren zur spezifischen stilllegung von h19
AU2008206643B2 (en) 2007-01-21 2013-09-19 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
CA2861840C (en) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2015034330A1 (ko) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 헬로퓨지농을 유효성분으로 포함하는 골질환 치료 또는 예방용 조성물
CN105497091B (zh) * 2016-01-05 2020-01-24 香港浸会大学 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Also Published As

Publication number Publication date
CA2280850C (en) 2004-01-13
EP1007044A4 (de) 2001-03-07
JP2001518075A (ja) 2001-10-09
US6420371B1 (en) 2002-07-16
WO1998034613A1 (en) 1998-08-13
ES2290983T3 (es) 2008-02-16
USRE39574E1 (en) 2007-04-17
ATE367158T1 (de) 2007-08-15
EP1007044B1 (de) 2007-07-18
KR100518106B1 (ko) 2005-10-04
US6028075A (en) 2000-02-22
IL131349A0 (en) 2001-03-19
AU738516B2 (en) 2001-09-20
IL131349A (en) 2004-08-31
DE69838099T2 (de) 2008-04-30
CA2280850A1 (en) 1998-08-13
KR20000070996A (ko) 2000-11-25
EP1007044A1 (de) 2000-06-14
AU6004998A (en) 1998-08-26

Similar Documents

Publication Publication Date Title
DE69838099D1 (de) Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
SE9901272D0 (sv) New improved formulation
ATE269066T1 (de) Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE60024414T2 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
DK1112083T3 (da) Behandling af mikrovaskulære angiopatier
TR199901104T2 (xx) Farmas�tik bile�ikler.
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
FI961380A0 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
DE69718156D1 (de) Polypflanzliche pharmazeutische Zusammensetzungen geeignet in der Behandlung der Hepatitis E und Hepatitis B Virus-Infektion zusammenhängenden Zustände
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
DK0850062T3 (da) Anvendelse af halofuginon til fremstilling af et medikament til svækkelse af neovaskularisering og til behandling af maligne tumorer hos mennesker
SE9803623D0 (sv) New therapeutic application
NO20030483D0 (no) Assosiasjoner av dalfopristin/quinupristin med cefpirom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee